| MINK THERAPEUTICS |
| USA |
| Gesundheit |
| US6036932019 / A40ZAV |
| 6Q40 (Frankfurt) / INKT (NASDAQ) |
| FRA:6Q40, ETR:6Q40, 6Q40:GR, NASDAQ:INKT |
| - |
| https://minktherapeutics... |
|
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies for ca..
>Volltext.. |
| 41.53 Mio. EUR |
| 34.17 Mio. EUR |
| - |
| -9.66 Mio. EUR |
| -10.64 Mio. EUR |
| -2.61 EUR |
| 4.93 Mio. EUR |
| 12.29 Mio. EUR |
| -4.8 Mio. EUR |
| 1.06 |
| - |
| 10.34% |
| - |
| - |
| - |
| MINK THERAPEUTICS, MINK THERAPEUTIC |
| 10.03.26 |
|
||||
|
||||
|